Gastrointestinal adverse effects of varenicline at maintenance dose: A meta-analysis

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Leung, Lawrence K ^a   Patafio, Francis M ^a   Rosser, Walter W ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; PLACEBO; QUINOXALINE DERIVATIVE;

ARTICLE; CONSTIPATION; DRUG DOSE TITRATION; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; MAINTENANCE DRUG DOSE; MEASUREMENT; META ANALYSIS; NAUSEA; NUMBER NEED TO HARM; PRACTICE GUIDELINE; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL DISEASE; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SMOKING CESSATION;

BENZAZEPINES; DOUBLE-BLIND METHOD; GASTROINTESTINAL DISEASES; HUMANS; MAINTENANCE CHEMOTHERAPY; NICOTINIC AGONISTS; PLACEBOS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION;

EID: 80053357028     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-15     Document Type: Article

References (36)

1. Peto R, Lopez AD, Boreham J, Thun M, Heath C, Doll R. Mortality from smoking worldwide. Br Med Bull 1996, 52(1):12-21.
2. Ezzati M, Lopez AD. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 2004, 13(4):388-395. 10.1136/tc.2003.005215, 1747946, 15564623.
3. Keating GM, Lyseng-Williamson KA. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010, 28(3):231-254. 10.2165/11204380-000000000-00000, 20108995.
4. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006, 60(5):571-576. 10.1111/j.1368-5031.2006.00955.x, 16700857.
5. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52(3):985-994. 10.1016/j.neuropharm.2006.10.016, 17157884.
6. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005, 48(10):3474-3477. 10.1021/jm050069n, 15887955.
7. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009, 31(3):463-491. 10.1016/j.clinthera.2009.03.021, 19393839.
8. Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J 2009, 6:25. 10.1186/1477-7517-6-25, 2760513, 19761618.
9. Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ 2010, 341:c6549. 10.1136/bmj.c6549, 2997603, 21134997.
10. Fagerstrom K, Nakamura M, Cho HJ, Tsai ST, Wang C, Davies S, Ma W, Lee TC, Russ C. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. Curr Med Res Opin 2010, 26(9):2165-2173. 10.1185/03007995.2010.505130, 20666691.
11. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010, 33(4):289-301. 10.2165/11319180-000000000-00000, 20297861.
12. Higgins JAD. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions 2008, 187-241. John Wiley and Sons, 1.
13. Sheehe PR. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health 1966, 56(10):1745-1750. 10.2105/AJPH.56.10.1745, 1257309, 5951494.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
15. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993, 2(2):121-145. 10.1177/096228029300200202, 8261254.
16. Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 2001, 322(7300):1479-1480. 10.1136/bmj.322.7300.1479, 1120528, 11408310.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 2127453, 9310563.
18. Cochran WG. The combination of estimates from different experiments. Biometrics Vol 1954, 10:101-129.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558. 10.1002/sim.1186, 12111919.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700. 10.1136/bmj.b2700, 2714672, 19622552.
22. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of Varenicline on Smoking Cessation in Mild-to-Moderate COPD: A Randomized Controlled Trial. Chest 2010,
23. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006, 166(15):1561-1568. 10.1001/archinte.166.15.1561, 16908788.
24. Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007, 23(4):793-801. 10.1185/030079907X182185, 17407636.
25. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006, 166(15):1571-1577. 10.1001/archinte.166.15.1571, 16908789.
26. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Williams KE. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007, 29(6):1027-1039. 10.1016/j.clinthera.2007.06.011, 17692719.
27. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296(1):56-63. 10.1001/jama.296.1.56, 16820547.
28. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007, 29(6):1040-1056. 10.1016/j.clinthera.2007.06.012, 17692720.
29. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010, 121(2):221-229. 10.1161/CIRCULATIONAHA.109.869008, 20048210.
30. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296(1):47-55. 10.1001/jama.296.1.47, 16820546.
31. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009, 14(3):384-392. 10.1111/j.1440-1843.2008.01476.x, 19192221.
32. Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, Williams KE, Billing CB. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008, 24(7):1931-1941. 10.1185/03007990802177523, 18513462.
33. Drossman DA. Rome III: the new criteria. Chin J Dig Dis 2006, 7(4):181-185. 10.1111/j.1443-9573.2006.00265.x, 17054578.
34. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005, 58(9):894-901. 10.1016/j.jclinepi.2005.01.006, 16085192.
35. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002, 31(1):88-95. 10.1093/ije/31.1.88, 11914301.
36. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335(7626):914-916. 10.1136/bmj.39343.408449.80, 2048840, 17974687.